Comparative gene expression of intestinal metabolizing enzymes

Area of Science:

• Pharmacology
• Genomics
• Biochemistry

Background:

• Drug metabolism significantly impacts oral drug efficacy and safety.
• Intestinal drug-metabolizing enzymes play a critical role in the prehepatic clearance of orally administered drugs.
• Understanding interspecies differences in these enzymes is essential for preclinical drug development and human risk assessment.

Purpose of the Study:

• To compare the gene expression profiles of drug-metabolizing enzymes in the intestine of mouse, rat, and human.
• To identify key phase I and phase II drug-metabolizing enzymes with differential expression across these species.
• To establish a genomic database for interspecies variations in intestinal drug metabolism.

Main Methods:

• Total RNA isolation from the duodenum of mice, rats, and humans.
• mRNA expression profiling using Affymetrix GeneChip oligonucleotide arrays.
• Quantitative analysis of gene expression for phase I (e.g., P450) and phase II (e.g., UGTs, GSTs, SULTs) drug-metabolizing enzymes.

Main Results:

• Significant interspecies variations were observed in the expression patterns of both P450 and phase II drug-metabolizing enzymes in the intestine.
• Specific examples of highly expressed enzymes in each species were identified, highlighting species-specific profiles.
• Approximately 40-60% of detected genes in the intestine were related to drug metabolism across the studied species.

Conclusions:

• Substantial interspecies differences exist in the intestinal gene expression of drug-metabolizing enzymes.
• This genomic data provides a valuable resource for improving predictions of intestinal prehepatic clearance of oral drugs.
• The findings underscore the importance of considering species-specific metabolic pathways in drug development and safety evaluations.